Shang Hai Zheng Quan Bao·2025-12-19 08:18Group 1 - The core point of the news is the appointment of Wang Lai as the new President of BeiGene, while the previous President, Wu Xiaobin, retains his position, leading to a "dual presidency" structure [2][4]. - Wang Lai has been with BeiGene since 2011 and has held various leadership roles in research, most recently serving as the Global Head of R&D since April 2021 [2][4]. - Wu Xiaobin has over 25 years of experience in the pharmaceutical industry and has been with BeiGene since 2018, previously holding significant positions at major pharmaceutical companies [4][6]. Group 2 - BeiGene is the first biotech company to be listed on NASDAQ, Hong Kong Stock Exchange, and Shanghai Stock Exchange, with two major products: the BTK inhibitor Bruton’s Tyrosine Kinase (Zebutinib) and the PD-1 inhibitor Tislelizumab [6]. - Zebutinib achieved global sales exceeding $1 billion for the first time in 2023, with total sales reaching $1.3 billion, marking it as the first drug in China to enter the "billion-dollar club" [6]. - For the first three quarters of 2025, BeiGene reported revenue of 27.595 billion yuan, a year-on-year increase of 44.2%, and a net profit attributable to shareholders of 1.139 billion yuan, successfully turning a profit [7][8].